Senior Associate Scientist, Biologics Downstream Process Development
Asimov
Summary
We are seeking a Senior Associate Scientist, Biologics Downstream Process Development to join our team in Boston, MA and help push the boundaries of biopharmaceutical and gene therapy process development. This role is for a technical expert who will conduct bioprocess engineering for biologics, design complex experimental approaches to improve our workflows and systems, apply scaling principles to both upstream and downstream processing (with emphasis on downstream), and coordinate interdepartmental project efforts.
Job description
The successful candidate will work closely with Asimov's synthetic biology, cell line development, and analytical development teams, along with interfacing with external partners. The role reports to the lead scientist for Downstream Process Development.
About the Role
- Perform clarifications, downstream processing/purification, and product quality assessment with analytical tools.
- Be involved hands-on in projects that include bioreactor scale-up (2L+) process development, harvest, and downstream process development.
- Serve as a technical subject matter expert (SME) in at-scale process development for both internal and external projects.
- Represent the process development team on cross-functional projects, making decisions for process development activities and effectively communicating results, progress, and plans.
- Work together with the strategic alliance and commercial teams to technology transfer developed processes and early-look materials to external partners.
- Partner with the software team to develop integrated data platforms and analysis for streamlined data analysis.
- Author, review, and approve process development reports and technology transfer protocols.
- Organize and document experiments and data in an electronic lab notebook.
About You
- MS in Biological Engineering, Chemical Engineering, Cell Biology, Molecular Biology, or a related field with minimum of 4 years of relevant hands-on experience in bioprocessing, or a Bachelors with minimum 6 years of hands-on industry experience.
- Downstream purification experience, optimizing ProA and UF/DF steps.
- Experience using chromatography systems and their HMI (i.e., AKTA/UNICORN).
- Mammalian (CHO) and/or viral vector process development experience.
- Creative problem solver excited to drive creation of industry-disruptive technology.
- Detail-oriented and highly organized.
- Expert in spreadsheets such as Google Sheets or Excel.
- Experienced using DOE software to develop robust experiments.
Requirements
- MS in Biological Engineering, Chemical Engineering, Cell Biology, Molecular Biology, or related field with minimum 4 years relevant hands-on bioprocessing experience, or Bachelors with minimum 6 years hands-on industry experience
- Downstream purification experience optimizing ProA and UF/DF steps
- Experience using chromatography systems and their HMI (AKTA/UNICORN)
- Mammalian (CHO) and/or viral vector process development experience
- Creative problem solver
- Detail-oriented and highly organized
- Expert in spreadsheets such as Google Sheets or Excel
- Experienced using DOE software to develop robust experiments
Benefits
- Stock options
- 401(k) plan
- Career development stipend
- Medical insurance
- Dental insurance
- Vision insurance
- Life insurance
- Disability insurance
- Flexible time-off
- Unlimited sick time
Company overview
Asimov is a pioneering synthetic biology company that builds tools to program living cells through the integration of mammalian synthetic biology, computer-aided design, and machine learning. Founded in 2017 by bioengineers from MIT and Boston University, the company develops an integrated platform combining cells, genetic tools, AI models, and software to design and manufacture next-generation therapeutics including biologics, cell/gene therapies, and RNA-based treatments. Headquartered in Boston, Massachusetts, Asimov's mission is to advance humanity's ability to design living systems, enabling biotechnologies with significant societal benefit. The company has raised over $200 million from top investors including Andreessen Horowitz, CPP Investments, Horizons Ventures, and Fidelity Management & Research Company, and has partnered with over 25 companies ranging from small biotechs to major pharmaceutical firms. Asimov's platform includes specialized systems like CHO Edge for biologics production, LV Edge for lentiviral vector manufacturing, and AAV Edge for gene therapy development, consistently delivering high-titer cell lines for advanced therapeutic applications.